
UB297
ProductAcarbose Tablets
Strength50mg; 100mg
IndicationsType 2 diabetes mellitus
TherapeuticsMetabolic & Endocrinology
GMPCN - NMPA; US - FDA
RegistrationUnited States
ModalitiesSmall Molecule
Exclusive Summary
- Backed by a US-FDA approved ANDA (ANDA213821 for 50/100mg strengths) which serves as a premier global quality endorsement, empowering rapid dossier adaptation and fast-track registration in emerging markets.
- Perfectly targets the rigid mass demand of over 537 million diabetic patients globally, exhibiting robust post-prandial blood sugar control that is highly essential for populations consuming high-carbohydrate diets.
- Maximizes China's mature API-to-FDF integrated supply chain to offer an FDA-standard product coupled with disruptive pricing, guaranteeing highly lucrative profit margins for distribution partners in tenders and private retail.
我们能如何帮助您?
获取最新活动与法规动态洞察
直接发送到您的邮箱
在此获取行业洞察与 Unibest 动态
联系我们 →